Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilaria Penna

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Oncotarget|December 19, 2015
Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockadeIlaria Penna, Alessandra Molla, Giulia Grazia, et al.
Chemmedchem|April 9, 2020
Multitarget Compounds for Bipolar Disorder: From Rational Design to Preliminary Pharmacokinetic EvaluationRita Maria Concetta Di Martino, Giovanni Bottegoni, Francesca Seghetti, et al.
Oncotarget|December 29, 2016
The inhibition of 45A ncRNA expression reduces tumor formation, affecting tumor nodules compactness and metastatic potential in neuroblastoma cellsIlaria Penna, Arianna Gigoni, Delfina Costa, et al.
Journal of Medicinal Chemistry|August 8, 2025
Exploration of the Neuromodulatory Properties of Fyn and GSK-3β Kinases Exploiting 7-Azaindole-Based InhibitorsGiambattista Marotta, Francesca Massenzio, Jose Ortega, et al.
Journal of Medicinal Chemistry|December 8, 2020
Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase InhibitorsSamantha Caputo, Simona Di Martino, Vincenzo Cilibrasi, et al.
Journal of Medicinal Chemistry|April 29, 2026
A Polypharmacology-Driven Approach to Alzheimer's Disease and Tauopathies: Rational Design, Synthesis and Characterization of Amino-Pyrazole-Based Multikinase (GSK-3β/FYN-α/DYRK1A) InhibitorsStefania Demuro, Debora Russo, Ilaria Penna, et al.
Journal of Medicinal Chemistry|March 17, 2020
Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase InhibitorsSimona Di Martino, Piero Tardia, Vincenzo Cilibrasi, et al.
Journal of Medicinal Chemistry|September 18, 2020
Identification, Structure-Activity Relationship, and Biological Characterization of 2,3,4,5-Tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indoles as a Novel Class of CFTR PotentiatorsNicoletta Brindani, Ambra Gianotti, Simone Giovani, et al.
Cancer Drug Resistance (Alhambra, Calif.)|October 23, 2025
Molecular targeting of the deubiquitinase USP14 to circumvent cisplatin resistance in ovarian carcinoma and identification of novel inhibitorsCristina Corno, Debora Russo, Francesco Pignotti, et al.
Journal of Medicinal Chemistry|September 1, 2021
Discovery and SAR Evolution of Pyrazole Azabicyclo[3.2.1]octane Sulfonamides as a Novel Class of Non-Covalent <i>N</i>-Acylethanolamine-Hydrolyzing Acid Amidase (NAAA) Inhibitors for Oral AdministrationPaolo Di Fruscia, Anna Carbone, Giovanni Bottegoni, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Oncotarget|December 19, 2015
Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockadeIlaria Penna, Alessandra Molla, Giulia Grazia, et al.
Chemmedchem|April 9, 2020
Multitarget Compounds for Bipolar Disorder: From Rational Design to Preliminary Pharmacokinetic EvaluationRita Maria Concetta Di Martino, Giovanni Bottegoni, Francesca Seghetti, et al.
Oncotarget|December 29, 2016
The inhibition of 45A ncRNA expression reduces tumor formation, affecting tumor nodules compactness and metastatic potential in neuroblastoma cellsIlaria Penna, Arianna Gigoni, Delfina Costa, et al.
Journal of Medicinal Chemistry|August 8, 2025
Exploration of the Neuromodulatory Properties of Fyn and GSK-3β Kinases Exploiting 7-Azaindole-Based InhibitorsGiambattista Marotta, Francesca Massenzio, Jose Ortega, et al.
Journal of Medicinal Chemistry|December 8, 2020
Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase InhibitorsSamantha Caputo, Simona Di Martino, Vincenzo Cilibrasi, et al.
Journal of Medicinal Chemistry|April 29, 2026
A Polypharmacology-Driven Approach to Alzheimer's Disease and Tauopathies: Rational Design, Synthesis and Characterization of Amino-Pyrazole-Based Multikinase (GSK-3β/FYN-α/DYRK1A) InhibitorsStefania Demuro, Debora Russo, Ilaria Penna, et al.
Journal of Medicinal Chemistry|March 17, 2020
Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase InhibitorsSimona Di Martino, Piero Tardia, Vincenzo Cilibrasi, et al.
Journal of Medicinal Chemistry|September 18, 2020
Identification, Structure-Activity Relationship, and Biological Characterization of 2,3,4,5-Tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indoles as a Novel Class of CFTR PotentiatorsNicoletta Brindani, Ambra Gianotti, Simone Giovani, et al.
Cancer Drug Resistance (Alhambra, Calif.)|October 23, 2025
Molecular targeting of the deubiquitinase USP14 to circumvent cisplatin resistance in ovarian carcinoma and identification of novel inhibitorsCristina Corno, Debora Russo, Francesco Pignotti, et al.
Journal of Medicinal Chemistry|September 1, 2021
Discovery and SAR Evolution of Pyrazole Azabicyclo[3.2.1]octane Sulfonamides as a Novel Class of Non-Covalent <i>N</i>-Acylethanolamine-Hydrolyzing Acid Amidase (NAAA) Inhibitors for Oral AdministrationPaolo Di Fruscia, Anna Carbone, Giovanni Bottegoni, et al.
Pageof 2